Heterocyclic inhibitors of tyrosine kinase
US11365189B2 · kind B2 · utility
0Cited by
1References
30Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 24, 2020 |
| Grant date | Jun 21, 2022 |
| Priority date | — |
| Expiry date | Apr 24, 2040 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D487/04
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
The present disclosure relates to heterocyclic compounds and methods which may be useful as inhibitors of HER2 or EGFR for the treatment or prevention of disease, including cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.